INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 134 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2019. The put-call ratio across all filers is 0.10 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $5,000 | +400.0% | 150 | 0.0% | 0.00% | – |
| Q3 2019 | $1,000 | -50.0% | 150 | 0.0% | 0.00% | – |
| Q2 2019 | $2,000 | 0.0% | 150 | 0.0% | 0.00% | – |
| Q1 2019 | $2,000 | 0.0% | 150 | 0.0% | 0.00% | – |
| Q4 2018 | $2,000 | -33.3% | 150 | 0.0% | 0.00% | – |
| Q3 2018 | $3,000 | 0.0% | 150 | 0.0% | 0.00% | – |
| Q2 2018 | $3,000 | 0.0% | 150 | 0.0% | 0.00% | – |
| Q1 2018 | $3,000 | +50.0% | 150 | 0.0% | 0.00% | – |
| Q4 2017 | $2,000 | 0.0% | 150 | 0.0% | 0.00% | – |
| Q3 2017 | $2,000 | 0.0% | 150 | 0.0% | 0.00% | – |
| Q2 2017 | $2,000 | 0.0% | 150 | 0.0% | 0.00% | – |
| Q1 2017 | $2,000 | 0.0% | 150 | 0.0% | 0.00% | – |
| Q4 2016 | $2,000 | 0.0% | 150 | 0.0% | 0.00% | – |
| Q3 2016 | $2,000 | -66.7% | 150 | 0.0% | 0.00% | – |
| Q2 2016 | $6,000 | +50.0% | 150 | 0.0% | 0.00% | – |
| Q1 2016 | $4,000 | -50.0% | 150 | 0.0% | 0.00% | – |
| Q4 2015 | $8,000 | +33.3% | 150 | 0.0% | 0.00% | – |
| Q3 2015 | $6,000 | – | 150 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 640,000 | $25,626,000 | 6.33% |
| Redmile Group, LLC | 1,322,592 | $52,957,000 | 4.01% |
| SENZAR ASSET MANAGEMENT, LLC | 556,224 | $22,271,209,000 | 3.24% |
| RA Capital Management | 314,349 | $12,587,000 | 1.81% |
| WALL STREET ASSOCIATES | 205,657 | $8,235,000 | 1.58% |
| Parametrica Management Ltd | 5,400 | $216,000 | 1.36% |
| Rhenman & Partners Asset Management AB | 165,000 | $6,607,000 | 1.05% |
| EAM Investors, LLC | 95,168 | $3,811,000 | 0.60% |
| Rock Springs Capital Management LP | 180,000 | $7,207,000 | 0.58% |
| WASATCH ADVISORS LP | 1,085,973 | $43,482,000 | 0.58% |